

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A nonapeptide selected from the group of peptides comprising the amino acid sequence of SEQ ID NO: 2, 3, 5, 8, 11, ~~or~~ and 12 or a peptide with cytotoxic T cell inducibility, wherein one, two, or more amino acids have been substituted or added to the amino acid sequence of SEQ ID NO: 2, 3, 5, 8, 11, or 12.
2. (Cancelled)
3. (Currently Amended) The peptide of claim 1 2, wherein the second amino acid from the N terminus is phenylalanine, tyrosine, methionine, or tryptophan.
4. (Currently Amended) The peptide of claim 1 2 or 3, wherein the C-terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine.
5. (Currently Amended) A nonapeptide or decapeptide selected from the group of peptides comprising the amino acid sequence of SEQ ID NO: 29, 30, 33, 34, 40, ~~or~~ and 46 or a peptide with cytotoxic T cell inducibility, wherein one, two, or more amino acids have been substituted or added to the amino acid sequence of SEQ ID NO: 29, 30, 33, 34, 40, or 46.
6. (Cancelled)
7. (Currently Amended) The peptide of claim 5 6, wherein the second amino acid from the N terminus is leucine or methionine.
8. (Currently Amended) The peptide of claim 5 6 or 7, wherein the C-terminal amino acid is valine or leucine.

9. (Currently Amended) A pharmaceutical for treating and/or preventing tumors, wherein the pharmaceutical comprises one or more peptides of claim 1 or 5, ~~any one of claims 1 to 8~~.
10. (Currently Amended) A pharmaceutical for treating diabetic retinopathy, chronic rheumatoid arthritis, psoriasis, and atherosclerosis, wherein the pharmaceutical comprises one or more peptides of claim 1 or 5, ~~any one of claims 1 to 8~~.
11. (Currently Amended) An exosome that presents on its surface a complex comprising a peptide of claim 1 or 5, ~~any one of claims 1 to 8~~, and an HLA antigen.
12. (Original) The exosome of claim 11, wherein the HLA antigen is HLA-A24 or HLA-A02.
13. (Original) The exosome of claim 12, wherein the HLA antigen is HLA-A2402 or HLA-0201.
14. (Currently Amended) A method for inducing an antigen-presenting cell with high cytotoxic T cell inducibility by using a peptide of claim 1 or 5, ~~any one of claims 1 to 8~~.
15. (Currently Amended) A method for inducing a cytotoxic T cell by using a peptide of claim 1 or 5, ~~any one of claims 1 to 8~~.
16. (Currently Amended) A method for inducing an antigen-presenting cell with high cytotoxic T cell inducibility, wherein said method comprises the step of introducing a gene that comprises a polynucleotide encoding a peptide of claim 1 or 5, ~~any one of claims 1 to 8~~ into an antigen-presenting cell.
17. (Currently Amended) An isolated cytotoxic T cell that is induced by using a peptide of claim 1 or 5, ~~any one of claims 1 to 8~~.
18. (Currently Amended) An antigen-presenting cell that presents a complex of an HLA antigen and a peptide of claim 1 or 5, ~~any one of claims 1 to 8~~.

19. (Currently Amended) The antigen-presenting cell of ~~claim 18, which is~~  
induced by the method of claim 14 ~~or 15~~.

20. (Currently Amended) A vaccine for inhibiting angiogenesis at a diseased  
site, wherein the vaccine comprises a peptide of claim 1 or 5 ~~any one of claims 1 to 8~~ as an active  
ingredient.

21. (Original) The vaccine of claim 20, which is used for administration to a  
subject whose HLA antigen is HLA-A24 or HLA-A02.

22. (Currently Amended) The vaccine of claim 20 ~~or 21~~, which is used to  
suppress the growth and/or metastasis of malignant tumors.